ArticleThe Journal of nutrition2026
Fish Consumption and Colorectal Neoplasms among Lynch Syndrome Carriers.
Article in The Journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFish intake may exert antineoplastic effects, potentially through omega-3 fatty acids. However, its role in the development of colorectal neoplasms (CRNs) among individuals with Lynch syndrome (LS), a genetic predisposition to colorectal cancer, remains unclear.
objectivesThe aim of this study was to examine the association between fish intake and CRN risk among LS carriers, overall and across subgroups defined by nonsteroidal anti-inflammatory drug/aspirin use, sex, geographical region, CRN history, and pathogenic variant type, and to examine associations between fish types and CRN risk.
methodsData from 1816 confirmed LS carriers in the GEOLynch cohort (The Netherlands) and the Colon Cancer Family Registry (Australia, Canada, and the United States) were used. Information on fish intake was collected at inclusion using food frequency questionnaires. CRNs included adenoma, serrated lesions, and colorectal cancer. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) across sex-specific quartiles and per 10 g/d of total fish intake. Associations for specific fish types were assessed per 5 g/d increase.
resultsDuring a median follow-up time of 7.0 y (IQR range: 2.8-13.6), 742 (40.9%) participants developed a CRN. The CRN risk was similar in individuals in the highest quartile of fish intake compared with the lowest quartile (HR 1.03; 95% CI: 0.81, 1.32). No association was observed for every 10 g/d increment in fish intake (HR: 1.0; 95% CI: 0.95, 1.05) and across subgroups. However, a 5 g/d increase in canned fish appeared to increase the risk of CRNs (HR: 1.06; 95% CI: 1.01, 1.10).
conclusionsTotal fish intake does not appear to influence the development of CRNs in individuals with LS, whereas the influence of canned fish intake on CRN risk should be further investigated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.